Am J Transplant, Volume 19, Suppl 3 Archives - Page 9 of 214 - ATC Abstracts

2019 American Transplant Congress
Infectious Complications of Eculizumab Use in Abdominal Organ Transplant Recipients
A. M. Nolan¹, E. J. Fraser², H. K. Grewal³, J. G. Timpone³
¹Department of Pharmacy, Medstar Georgetown University Hospital, Washington, DC, ²Georgetown University School of Medicine, Washington, DC, ³Division of Infectious Diseases and Travel Medicine, Medstar Georgetown University Hospital, Washington, DC
*Purpose: The purpose of this study is to identify and characterize infections in abdominal organ transplant recipients related to treatment with eculizumab. Eculizumab (Soliris®) is…
2019 American Transplant Congress
Tertiary Lymphoid Organs in Renal Chronic Allograft Rejection
K. Abou-Daya, D. Zhao, A. Williams, M. Oberbarnscheidt
Starzl Transplantation Institute, Pittsburgh, PA
*Purpose: Chronic allograft rejection remains a major obstacle to long-term allograft survival. Tertiary lymphoid organs (TLOs) are ectopic lymphoid structures that arise in non-lymphoid tissues…
2019 American Transplant Congress
CD46 Transgene Modification and Thrombosis in Neonatal Porcine Islet Xenotransplantation
M. Song, K. Samy, Q. Gao, R. P. Davis, F. Leopard, Z. Fitch, C. Bennett, G. R. Devi, B. H. Collins, A. D. Kirk
Surgery, Duke University, Durham, NC
*Purpose: Vascular thrombosis activation is an important cause for early xeno-islet loss. To better understand the thrombosis process in islet xenotransplantation and the effect of…
2019 American Transplant Congress
The Collaborative Improvement and Innovation Network (COIIN): Impact on Deceased Donor Transplant Rates and Offer Acceptance Practices
A. Wey¹, S. Gustafson¹, B. Carrico², J. Foutz², K. Sisaithong³, M. McBride², D. Klassen², D. Klassen², N. Salkowski¹, B. Kasiske¹, A. Israni¹, J. Snyder¹
¹SRTR, Minneapolis, MN, ²OPTN, Richmond, VA, ³OPTN, Minneapolis, MN
*Purpose: The Organ Procurement and Transplantation Network (OPTN) completed the Collaborative Improvement and Innovation Network (COIIN), a study to increase kidney transplants by reducing risk…
2019 American Transplant Congress
How Do We Choose? Predicting Utilization Of Cardiac Donors And The Effect Of Era
D. A. Baran¹, J. T. Lansinger², A. Long², J. Philpott³, H. Copeland⁴, W. Old³, G. Zeevi³, C. Barreiro³, C. Kemp³, B. H. Smith³, K. Stelling³, A. Ingemi³, P. Bourassa³, J. M. Herre³
¹Sentara Heart Hospital, Virginia Beach, VA, ²Eastern Virginia Medical School, Norfolk, VA, ³Sentara Heart Hospital, Norfolk, VA, ⁴University of Mississippi Medical Center, Jackson, MS
*Purpose: The number of patients on the heart transplant waitlist continues to rise. However, the rate of organ acceptance is only about 1/3 of all…
2019 American Transplant Congress
Clazakizumab as an Agent to Reduce Donor Specific HLA Antibodies and Improve Outcomes in Patients with Chronic & Active Antibody-Mediated Rejection Post-Kidney Transplantation
S. C. Jordan¹, N. Ammerman¹, M. Toyoda², E. Huang¹, C. C. Nast³, A. Peng¹, S. Sethi¹, R. Najjar¹, I. Kim¹, K. Lim¹, J. Choi¹, A. Vo¹
¹Comprehensive Transplant Center, Cedars-Sinai Medical Ctr, Los Angeles, CA, ²Transplant Immunology Lab, Cedars-Sinai Medical Ctr, Los Angeles, CA, ³Department of Pathology, Cedars-Sinai Medical Ctr, Los Angeles, CA
*Purpose: Highly sensitized (HS) patients are at an increased risk for chronic antibody mediated rejection (cABMR) and graft loss due to persistent, deleterious DSA production.…
2019 American Transplant Congress
Letermovir For The Treatment And Secondary Prophylaxis Of Drug Resistant CMV In Solid Organ Transplant Recipients
M. R. Pereira¹, J. G. Aaron¹, C. J. Kubin²
¹Medicine - Infectious Diseases, Columbia University Medical Center, New York, NY, ²Medicine - Infectious Diseases, NewYork Presbyterian Hospital, New York, NY
*Purpose: Although only approved for primary prophylaxis of CMV among allogeneic stem cell transplant recipients, there is great interest in the use of letermovir (LET)…
2019 American Transplant Congress
Antithymocyte Globulin is Associated with Mature T Cell Phenotypes and Decreased Risk of Non-EBV Infections in Transplanted Children
B. I. Shaw¹, L. Stempora¹, C. Chan¹, R. B. Ettenger², P. C. Grimm³, H. Lee¹, E. F. Reed², M. M. Sarwal⁴, B. L. Warshaw⁵, C. Zhao¹, O. M. Martinez³, A. D. Kirk¹, E. T. Chambers¹
¹Pediatrics/Surgery, Duke University, Durham, NC, ²Pediatrics, University of California, Los Angeles, Los Angeles, CA, ³Pediatrics/Surgery, Stanford University, Palo Alto, CA, ⁴Pediatrics/Surgery, University of California, San Francisco, San Francisco, CA, ⁵Pediatrics, Emory University, Atlanta, GA
*Purpose: Depletional induction therapies are known to reduce the rate of acute rejection; yet data from the US Renal Data System have shown that use…
2019 American Transplant Congress
The Protective Effects of siRNA Conjugated Nanoparticles in Pancreatic Islet Cells after Transplant
T. Pomposelli, P. Wang, Y. Ariyoshi, K. Takeuchi, C. Schuetz, A. Moore, K. Yamada
Columbia Center for Translational Immunology, Columbia University, New York, NY
*Purpose: To utilize a novel technology involving siRNA conjugated iron oxide nanoparticles to protect against ischemic damage to islet cells before transplant, therefore minimizing the…
2019 American Transplant Congress
Risk Factors to Define an Extended Criteria Donor Heart Do Not Appear to Have Cumulative Adverse Effects after Heart Transplantation
M. Olymbios, S. Dimbil, R. J. Levine, F. Esmailian, J. Patel, J. A. Kobashigawa
Cedars-Sinai Smidt Heart Institute, Los Angeles, CA
*Purpose: There remains a disparity between the number of patients awaiting heart transplantation (HTx) and the availability of donor hearts. This is exacerbated by relatively…

« Previous Page
1
…
7
8
9
10
11
…
214
Next Page »